ROIV — Roivant Sciences Ltd.
$39.53
$-0.46 (-1.15%)
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Market Cap
$28.64B
Forward P/E
-24.5x
52-Week Range
N/A
ROIV Price History
Revenue vs. Net Income
$8.3M
Revenue · FY2026
Annual. Net margin is shown under each year.
Free Cash Flow
-$759M
FCF · FY2026
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-23.7%
ROCE · FY2026
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.8x
Assets ÷ liabilities · FY2026
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
99.4%
CapEx · FY2026
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-4.3%
Net buyback · FY2026
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
